104525First steps in scaling up Medherant's transdermal patch manufacturing capabilities to cGMPClosedFeasibility StudiesISCF"Medherant seeks to become the world's leading developer of transdermal drug products and has the technology platform, scientific expertise and R&D capabilities to do so. We are developing our own best-in-class products to out-license to global pharma marketing partners alongside offering contract formulation services for companies seeking to develop novel transdermal products using our unique TEPI patch platform technology. Medherant has a global exclusive licence to a truly revolutionary suite of adhesive polymers developed by Bostik S.A. which allow the formulation of a much wider range of drugs at much higher loadings than existing adhesives and with better rates flux across the skin. Our TEPI patches also have excellent consumer benefits such as strong adhesion, they are waterproof and easy to remove and they don't leave unsightly black marks. We have developed a novel patent pending system which enables us to perform high-throughput skin permeation studies which in turn allows us to formulate and test novel patch products in a fraction of the usual time seen within the industry. Such advantages have already been leveraged to attract interest from pharmaceutical companies across the globe and we have already successfully completed feasibility studies for a large European company and one of Japan's largest transdermal pharma companies. Our services are in demand - we are in contract negotiations for feasibility studies with a number of large international companies and are in serious discussions with other potential clients with whom we hope to fill our R&D capacity for 2018\. We have recently installed our own pilot-scale in-line patch manufacturing plant (January 2018) and have already successfully produced patches of our own ibuprofen patch and a batch of patches for our Japanese client which are being used in pre-clinical studies. To meet our own future demands and commercial ambitions and to expand our service offering to clients for our formulation services we now need to expand our in-house manufacturing capabilities and to start the process of upgrading those facilities to produce clinical grade materials. This funding will support the expansion of our current formulation and production capabilities and to plan the future work neccessary for us to obtain the GMP certification which will allow us to manufacture patch materials suitable for clinical trials."